Patrick R Harrington

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment
    Patrick R Harrington
    Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, MD 20993, USA
    Hepatology 55:1048-57. 2012

Collaborators

Detail Information

Publications1

  1. doi request reprint Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment
    Patrick R Harrington
    Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, MD 20993, USA
    Hepatology 55:1048-57. 2012
    ..Eligibility for shortened treatment duration should be based on achieving undetectable HCV RNA (i.e., HCV RNA not detected) at RGT decision timepoints...